Access Scientific is establishing a new standard of over-wire vascular access with its proprietary WAND® technology which is designed to provide the fastest, safest and simplest method of catheter insertion. The device was developed at Yale University by Dr. Michael Tal, an associate professor of radiology in at the Yale University School of Medicine and a recognized expert in the field of vascular access.
Achillion Pharmaceuticals is an innovative leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases. The company was founded by Tommy Cheng, a Yale professor of pharmacology, and the New Haven-based startup raised $50.1 million in venture funding and another $41.8M through direct offering.
Advanced Orthopedic Technologies is commercializing an innovative approach to repairing cartilage lesions of the ankle and knee with allograft material or autografts using joints in the foot. The company is developing proprietary tools for obtaining, shaping and implanting cartilage grafts. This novel surgical approach was pioneered by Dr. John Reach, head of the Foot and Ankle Division of Orthopedics at Yale.
Affomix Corporation developed technology to permit high throughput production and screening of antibodies against virtually all human proteins, both as encoded and post-translationally modified, and was founded, in part, on research licensed by Affomix that was developed at a large pharmaceutical company. The company was cofounded by two Yale scientists—Michael Snyder, who is now at Stanford, and Sherman Weissman, Sterling Professor of Genetics at Yale. It was purchased by Illumina in July 2010.
Ancera uses a Yale-patented technology platform for the separation, detection and identification of minute concentrations of microorganisms, proteins or DNA from complex matrixes—including blood, food and cancerous tumors. The company was cofounded by Arjun Ganesan (SOM ’12) and Hur Koser, a former Associate Professor of Electrical Engineering at Yale. Ancera’s technology uses magnetic fields to manipulate biologic cells via a ferromagnetic fluid and the company anticipates that its technology platform will be useful in food safety testing, point-of-care diagnostics and in vitro diagnostics.
Artizan Biosciences is based on the discovery made by founders Dr. Richard Flavell, Noah Palm, PhD, and Marcel de Zoete, PhD in Yale’s Department of Immunobiology that they could distinguish certain pathogenic bacteria from the remainder of the intestinal microbiota. The ability to target these specific bacteria could lead to treatment options for a number of digestive disorders as well as other diseases including obesity, autoimmune disease, and a wide variety of skin, lung and central nervous system diseases.
Arvinas is a pharmaceutical company focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Central to Arvinas’ proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. This new class of drugs could target proteins that are not currently ‘druggable’ using a small molecule approach. Arvinas is built on the research of Craig Crews, Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology and professor of Chemistry and Pharmacology at Yale.
Based on the work of Tso-Ping Ma, AUCMOS is implementing a unipolar cmos layout in Si-based IoT circuits and smart sensors to reduce fabrication cost and power consumption.
A “sister company” of New Haven-based C8 Sciences, BeCaid China is developing Internet-delivered brain development programs that are integrated with physical exercise for the Chinese market. Cofounded by Yale’s Bruce Wexler and Jinxia Dong.
Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Founders include Vlad Coric, John Krystal and Gerard Sanacora from Yale Deparptment of Psychiatry.
C8 Sciences is a scientifically-based cognitive cross training program shown to increase test scores. Designed neuroscientists from Yale University, the program integrates web-based computer games and physical exercise, and strengthens core cognitive capacities such as attention, memory, and focus for Kindergarten through third grade. Bruce Wexler, professor emeritus of psychiatry at Yale School of Medicine, is one of the cofounders.
CardioPhotonics has developed proprietary technology to identify and develop noninvasive products which detect and interpret changes in fluid volume. Their first product is specifically designed to measure blood volume in emergency care facilities that will allow doctors to facilitate clinical decisions and improve patient outcomes. The company was founded in 2009, based on technology resulting from the research of two professors of anesthesiology at Yale: Kirk Shelley and David Silverman.
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed by John Rose, Professor of Pathology, at Yale University School of Medicine. The company has developed viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
CavtheRx is focused on the development of a novel class of modulators of caveolin function with applicability to multiple sclerosis, uveitis, inflammatory bowel disease and traumatic brain injury. The core technology was developed in the laboratory of Yale Professor William Sessa and enables the modulation of signal transduction in vascular endothelial cells by a wide variety of cytokines.
CGI Pharmaceuticals was a development-stage pharmaceutical company that has leveraged its small molecule chemistry and kinase biology expertise to discover and develop an innovative pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It was founded by Mark Velleca, Assistant Clinical Professor of Laboratory Medicine at Yale, and acquired by Gilead Sciences in June 2010.
ContraMed is an early-stage company that was founded to develop novel contraceptive devices which are intended to dramatically change the paradigm of sterilization and intra-uterine devices by being minimally invasive and inserted on an outpatient basis. The company’s technology has been exclusively licensed from Yale University and is based on the inventions of Michael Tal, assistant professor at Yale and attending physician at Yale New Haven Hospital.
CoolSpine™ is a medical device spin-out from Yale University that has developed a cerebral spinal fluid cooling platform designed to induce localized hypothermia and prevent neurological injuries such as paraplegia and brain damage by reducing the consequences of spinal cord and cerebral ischemia. It was cofounded by Dr. John Elefteriades, William W.L. Glenn Professor of Cardiothoracic Surgery and Chief of Cardiothoracic Surgery at Yale University and Yale New-Haven Hospital.
Cybrexa Therapeutics is an oncology-focused biotechnology company based on the work of Yale facutlyRanjit S. Bindra and Peter Glazer. Cybrexa is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment.
GestVision, led by founder and CEO Wendy Davis, A Yale School of Mangament alumna, is commercializing a point of care diagnostic test for preeclampsia based on inventions by former Yale faculty Irina Buhimschi. GestVison was part of the YEI Venture Creation program.
GLG Pharma, a Florida biotechnology company, is developing a series of patented inhibitors to treat a wide variety of cancers with potentially greater efficacy and fewer side effects than existing therapies. The company was cofounded by Andrew Hamilton, former Provost and former chair of the Dept. of Chemistry at Yale who is currently Vice-Chancellor of the University of Oxford.
goBlue combines mindfulness training with 21st century technology in order to help people improve their life and work. The foundational research that underlies goBlue’s technology was developed at Yale University in the lab of Judson Brewer, assistant professor of psychiatry at Yale. The company’s web/smartphone smoking cessation program has been shown to be twice as effective as the leading quit smoking therapy.
Great Basin Corporation is dedicated to developing simple yet powerful point-of-care technology and products that improve automation, throughput, scalability, reliability and ease-of-use in sample-to-result molecular diagnostic testing. The company is licensing thin-film biosensor technology developed by founder David C. Ward while at the Yale University School of Medicine.
Hadapt has developed the industry’s only Big Data analytic platform natively integrating SQL with Apache Hadoop. The unification of these traditionally segregated platforms enables customers to analyze all of their data in a single platform. The company was founded by Yale computer science professor Daniel Abadi and Justin Borgman, a former student with the Yale School of Management. Hadapt was acquired by Teradata in July 2014.
HistoRx is developing novel diagnostic solutions to enable new approaches to individualized patient care. Specifically, the company is focused on analysis of protein biomarkers using its proprietary technology and then correlating protein expression with disease outcome. Three breast cancer assays were launched in 2010. The company, founded by David Rimm, M.D., and Robert Camp, M.D., both in the Department of Pathology at Yale, was acquired by Genoptix in Sept. 2012.
Hygeia Therapeutics is developing topical hormone therapeutics to treat acne, excess facial hair, baldness and vulvar and vaginal atrophy. These therapies are based on patents held by Yale University and developed at Yale Medical School. Now part of Diffusion Pharmaceuticals.
Iconic Therapeutics is an Atlanta, Georgia-based biopharmaceutical company with an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1™. This protein triggers natural killer cells to selectively destroy cells related to age-related macular degeneration and cancer.
Developing a therapeutic for pediatric congenital heart disease, based on work by Anton Bennett, Yale Professor of Pharmacology and of Comparative Medicine.
Immunova has a proprietary Nanolipogel™ platform to deliver desired combinations of drugs in nanoparticle formulations to the disease microenvironment. Immunova’s scientific co-founders are Tarek Fahmy, Yale Associate Professor of Biomedical Engineering and of Immunobiology and Ephraim Fuchs of Johns Hopkins.
Inozyme is working on a therapeutic for rare cardiac disease and is based on the work of Yale Associate Professor of Pathothogy, Demetrios Braddock.
Insero Health is a clinical stage company that discovers and develops small molecule therapies derived from natural products to address significant unmet needs in neurological diseases. Insero is a spinout of Harvard Medical School and has licensed technology from Yale University to support its clinical, research and discovery programs. The company’s initial target is epilepsy.
IsoPlexis has a proprietary single-cell immunoassay and software suite that emerged from the lab of Rong Fan, assistant professor of biomedical engineering at Yale, together with Yale students Kara Brower and Sean Mackay. The startup was formed through the Technology Commercialization Program at the Office of Cooperative Research and the Yale Entrepreneurial Institute.
JS Genetics develops and markets proprietary, low cost, high value DNA diagnostic tests for underserved medical conditions in newborns, children, and adolescents. Cofounder Jeff Gruen is an associate professor of Pediatrics, Genetics and Investigative Medicine Program at Yale; cofounder Scott Rivkees was a professor of pediatrics at Yale and director of the Yale Child Health Research Center who is now professor and Chairman of Pediatrics at the University of Florida.
Based on discoveries by David Spiegel, Yale Professor of Chemistry, this biotechnology company is pioneering a new class of immunotherapies utilizing small molecules to activate an individual’s own immune system to fight against cancers and infectious diseases.
Kolltan Pharmaceuticals is developing cancer therapeutics. Kolltan’s primary targets derive from seminal discoveries made in the laboratory of Joseph Schlessinger, chairman of the Department of Pharmacology at the Yale School of Medicine. Kolltan was acquired by Celldex in November 2016.
L2 Diagnostics is a Yale-based company that is working to develop diagnostics and therapeutics for Lyme Disease, West Nile Virus, Tuberculosis and other diseases.
LIFNano Therapeutics was founded by Tarek Fahmy, Yale Associate Professor of Biomedical Engineering and of Immunobiology, and his collaborator Su Metcalfe at University of Cambridge. A nano-therapeutic approach focused on targeted delivery of the biologic, Leukemia Inhibitory Factor (LIF), is being developed to treat chronic inflammatory diseases, initially multiple sclerosis.
MZ Diagnostics develops, validates, and commercializes diagnostic applications for implementation on mass spectrometry platforms that address critical clinical needs. The company was cofounded by Michael E. Hodsdon, associate professor of laboratory medicine and of pharmacology and associate director of the Clinical Chemistry Laboratory at Yale; Thomas Murray, assistant professor of laboratory medicine at Yale; and David Ryan Peaper, assistant professor of laboratory medicine and director of the Clinical Microbiology Laboratory at Yale.
Melinta Therapeutics is dedicated to discovering, developing and commercializing urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. Antibiotics being developed by the company stem from the groundbreaking research of two Yale professors—Thomas Steitz in molecular biophysics and biochemistry and Peter Moore in chemistry.
A software company that is developing a new class of graphical-media-design system developed by Yale Professor Julie Dorsey that lies between today’s 2D digital draw-and-paint systems and 3D computer-aided design systems.
MGS Research, based in Madison, Connecticut, is dedicated to inventing, developing and commercializing new products and services in the area of three-dimensional radiation dosimetry for therapeutic and diagnostic radiology. The company was founded by three co-inventors at Yale: Marek J. Maryanski, John C. Gore and Robert J. Schulz.
MIFCOR is commercializing MIF-based therapeutics that treat ischemic conditions (reduce tissue damage from disease) in the heart, kidney, and brain, as well as in peripheral vascular disease. The compounds also have application to organ transplant. The company is based on discoveries by Richard Bucala, M.D., Ph.D, Yale Professor of Medicine.
MiraDx has a mission to dramatically improve assessment of individual cancer risk and cancer biology through the development of genetic markers. The company has licensed technology from Yale related to microRNA-disrupting genetic variants that can be used to predict a patient’s risk of developing triple negative breast cancer.
Modulate Therapeutics is a special purpose company created to develop one compound, IMM-01, to proof-of-concept. The nanogel delivery system platform was developed in the lab of Tarek Fahmy, Yale Associate Professor of Biomedical Engineering and of Immunobiology.
NextCure is focused on discovering and developing next generation immunotherapy-based biologics for cancer and other immune-related disorders. NextCure was founded by Lieping Chen, M.D., Ph.D., United Technologies Professor of Cancer Research, Professor of Immunobiology, Dermatology, and of Medicine at the Yale School of Medicine.
NovaTract is a venture-backed startup company founded to develop new, innovative laparoscopic medical devices for surgeons to take minimally invasive surgery to the next level of ease and simplicity. The company’s entry product addresses the need to increase visibility by using fewer instruments, provide dynamic retraction, and reduce the number of trocar ports and incisions. The company, founded by Kurt Eric Roberts, Associate Professor of Surgery (Gastrointestinal) at Yale, was acquired by Caldera Medical in 2016.
Nucleus Therapeutics Pty Ltd is developing an anti-DNA antibody platform discovered by James Hansen and Peter Glazer in Yale’s department of Therapeutic Radiology. Acquired by Patrys.
Founded by environmental engineering doctoral student Rob McGinnis (’02, Ph.D. ’09), Oasys uses a Yale-patented technology for forward osmosis that relies on a proprietary solution to draw salt out of seawater to produce drinking water after vaporization at much lower temperatures than other thermal desalination. Oasys’ technology is now being used to clean water used in hydraulic fracturing operations.
Omnis Pharmaceuticals is a clinical stage biotechnology company dedicated to delivering groundbreaking virus-based therapies for cancer patients, based on discoveries by John K. Rose, Yale Professor of Pathology. Omnis’ lead program employs the VSV (vesicular stomatitis virus) platform, which has been strategically engineered to selectively destroy cancer without harming normal tissues. Omnis Pharma and Magnis Therapeutics merged to form Vyriad, a clinical-stage oncolytic immunovirotherapy development company in March 2016.
Optherion is a biotechnology company that is developing diagnostic and disease-modifying products for the management and treatment of dry and wet Age-Related Macular Degeneration and other chronic diseases. Dry AMD is the leading cause of blindness in people over 60 in the developed world. The company is licensing IP from Josephine Hoh, associate professor of epidemiology at Yale.
Osmol Therapeutics is developing a therapy for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) and Neurologic Impairment, based on work discovered by Yale Professor Barbara Ehrlich.
P2 Science is a renewable chemicals company that has developed a unique bio-refining process for the conversion of biomass, including vegetable oils, into high-value specialty chemicals including flavor and fragrance ingredients. Patrick Foley, a graduate of the PhD program in Environmental Engineering at Yale, is P2′s Chief Scientific Officer.
This specialty oncology company and its novel cancer drug candidate GGTI-2418 was acquired by Prescient Therapeutics in May 2014. Former Yale Professor Andrew Hamilton and the Moffitt Cancer Center were involved with the invention.
Detecting, targeting and treating acidic diseased tissue using selective insertion and folding of membrane peptides. The primary application market is oncology. This is a collaboration between Donald Engelman, Eugene Higgins Professor of Molecular Biophysics and Biochemistry at Yale and laboratories at the University of Rhode Island.
Through exclusive agreements with Yale School of Medicine and Yale-New Haven Hospital, Precipio offers comprehensive pathology reports to oncologists, hospitals and patients. Precipio has also licensed cutting-edge diagnostic tests and technologies from Yale, such as the tumor profiling testing suite and a patented prognostic biomarker for ovarian cancer, discovered at Yale.
Proteolix was a biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. Proteolix’s lead compound, Carfilzomib/Kyprolis™, was developed by Craig Crews, Lewis B. Cullman Professor of Molecular, Cellular, and Developmental Biology at Yale. The company was acquired by Onyx Pharmaceuticals for $276 Million in Oct. 2009.
Protometrix was a biotechnology company focused on the production and investigation of the function and interaction of proteins in parallel using nanoscale technology and collecting that information in an informatics database. The technology was developed by Michael Snyder, a former Yale molecular biologist who is now professor and chair of genetics at Stanford. The company was acquired by Invitrogen in April 2004.
QCI’s long-term goal is to develop, manufacture, and sell the first practical and useful quantum computers based on superconducting devices. Along the way to building a quantum computer, QCI will commercialize the components, devices, and software that will accelerate basic research and enable the scaling of quantum computing. QCI was founded by three scientists from the Department of Applied Physics at Yale University: Michel Devoret, Luigi Frunzio, and Robert Schoelkopf.
Rachiotek is developing the Stabilimax™ Dynamic Spine Stabilization System, a posterior dynamic stabilization device designed to support an injured or degenerated spine without eliminating motion. The device was developed at Yale University Medical School.
ReNetX Bio, formerly known as Axerion Therapeutics, is a private New Haven-based biotechnology company focused on developing innovative therapeutics for neurological diseases and injuries with significant unmet medical need, including Alzheimer’s disease and spinal cord injury. ReNetX is developing and commercializing intellectual property licensed from Yale University based on work done by Dr. Stephen Strittmatter, Vincent Coates Professor of Neurology and Professor of Neurobiology at Yale.
Seldera is developing scalable, secure, intelligent sensing solutions for building energy efficiency. The company is headquartered in New Haven, Conn., and was founded by Andreas Savvides, former Barton L. Weller Associate Professor of Electrical Engineering and Associate Professor of Computer Science at Yale. Seldera is now an Ameresco Company.
Cofounded by Max Uhlenhuth (YC ’12) and Zack Parisa (FES ’09), SilviaTerra’s proprietary software uses satellite images with limited ground monitoring for cost-efficient and accurate forest management from afar. The company, which launched from a Yale Entrepreneurial Institute Summer Fellowship, has now worked with hundreds of foresters and has developed a free app—Plot Hound—for navigating and recording tree data on the go.
Spring Care is an online data-driven tool that matches depression patients with treatment options to which they are more likely to respond. Yale students Adam Chekroud GRD ’20, Abhishek Chandra ’16 and April Koh’16 started Spring Care based on an algorithm devised by Chekround as part of his PhD in psychology.
Supercool Metals commercializes bulk metallic glasses (BMGs). BMGs, also called Liquidmetals or amorphous metals, look like ordinary metal solids but are stronger than steel and can easily be shaped like plastics. Supercool uses sheets as a versatile feedstock material, allowing customers to fabricate complex shapes with precision and ease. The processing method is based on recent scientific discoveries by Jan Schroers, a Yale University professor of mechanical engineering and materials science.
Physiologic Immunotherapy of Cancer and Auto-aggressive Immunologic Disorders. Researchers and physicians at Medical School of Dermatology have been among the pioneers of the extracorporeal photopheresis and transimmunization and maintain a strong position in that field. Transimmune works closely with the Professor Edelson’s lab to build on the previous decades of insight surrounding extracorporeal photopheresis.
Tummyzen is an over-the-counter immediate release antacid supplement. The product is based on innovative, patented research by Dr. John Geibel, Vice Chair of Surgery at Yale. The active ingredients are classified by the FDA as GRAS (Generally Regarded as Safe), and the zinc-based formula is as effective and lasts four times longer than calcium carbonate, the leading active ingredient in common antacids on the market today. Tummyzen has a regional distributor and is anticipating national expansion.
Vascular Insights develops, manufactures and markets devices to treat varicose vein disease, based on technology invented by Michael Tal, M.D., assistant professor of diagnostic radiology and director of research interventional radiology at Yale University School of Medicine.
VaxInnate has developed a dramatically improved vaccine platform and vaccines for infectious diseases, including seasonal and pandemic flu, dengue and Clostridium difficile. The company was founded in 2002 by Ruslan Medzhitov and Richard Flavell, both of Yale University and Howard Hughes Medical Institute and leaders in the field of innate immunity.
Vedanta is using its proprietary platform to discover and develop a novel class of drugs that modulate pathways of interaction between the human microbiome and the host immune system to treat disease. It was cofounded by Ruslan Medzhitov, David W. Wallace Professor of Immunobiology at Yale School of Medicine, who has pioneered our current understanding of the innate immune system.
Startup founded by Stephen Dellaporta, Yale Professor of Molecular, Cellular, and Developmental Biology. Verinomics uses genomics, computational biology and statistical analysis to provide solutions for crop improvement.
Vidus Ocular was developing the Aquashunt,™ a glaucoma drainage device that can relieve elevated pressure in patients with or at risk for the development of glaucoma. It was cofounded by Dr. Bruce Shields, Marvin L. Sears professor and chairman emeritus of the Department of Ophthalmology at Yale School of Medicine. The company was acquired by Opko Health in May 2008.
Vutara enables researchers to study the structures and processes of cells at the single-molecule level by delivering the first ever super-resolution, single-molecule localization microscope with 3D capability. Vutara’s ResEnhanced technology employs proprietary algorithms developed by Joerg Bewersdorf and his lab at Yale to acquire super-resolved images in seconds.
Yiviva is a biotechnology company, co-founded by Yale University, Yung-Chi Cheng, PhD, Peikwen Cheng, MBA, and Shwu-Huey Liu, PhD, to develop evidence-based botanical products to address aging-associated diseases.